From NAFLD to HCC: Advances in noninvasive diagnosis

Biomed Pharmacother. 2023 Sep:165:115028. doi: 10.1016/j.biopha.2023.115028. Epub 2023 Jun 16.

Abstract

Non-alcoholic fatty liver disease (NAFLD) has gradually become one of the major liver health problems in the world. The dynamic course of the disease goes through steatosis, inflammation, fibrosis, and carcinoma. Before progressing to carcinoma, timely and effective intervention will make the condition better, which highlights the importance of early diagnosis. With the further study of the biological mechanism in the pathogenesis and progression of NAFLD, some potential biomarkers have been discovered, and the possibility of their clinical application is gradually being discussed. At the same time, the progress of imaging technology and the emergence of new materials and methods also provide more possibilities for the diagnosis of NAFLD. This article reviews the diagnostic markers and advanced diagnostic methods of NAFLD in recent years.

Keywords: Fibrosis; HCC; NAFLD; NASH; Noninvasive diagnosis.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / pathology
  • Fibrosis
  • Humans
  • Liver / pathology
  • Liver Cirrhosis / pathology
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / pathology
  • Non-alcoholic Fatty Liver Disease* / pathology

Substances

  • Biomarkers